Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Not only balloons: Use-cases and key players in global helium market

Whether you’re seeking exposure to exploration upside or established profitability, the helium market offers compelling candidates for the commodity sleeve of your portfolio. Helium is an essential resource notable for its widespread use-cases and p...
Trevor Abes | September 5, 2024 |

Revolutionary biopharma company makes waves across the globe

The following is a transcription of the above video, and The Market Online has edited it for clarity . The Market Online recently caught up with NurExone Biologic Inc (TSXV:NRX) , a revolutionary biopharmaceutical company developing regenerative medicine therapies,...
Lyndsay Malchuk | July 10, 2024 |

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
Knox Henderson | July 2, 2024 |

2024, a breakthrough year for silver

By Chen Lin, chenpicks.com For thousands of years, silver has been a globally recognized commodity. In China, silver was historically used as a standard form of currency, and the term “bank” in Chinese (银行) literally translates to “silver tradi...
Research | June 14, 2024 |

Minnesota helium project well positioned to help alleviate global shortage

By Marc Farrington In February this year, Pulsar Helium Inc (Pulsar) ( TSXV:PLSR ) announced extraordinarily high helium concentrations of up to 13.8% from its Jetstream No. 1 appraisal well drilled at its Topaz project in Minnesota. This has positioned Topaz as th...
Research | May 9, 2024 |

Buzz on the Bullboards: The top stocks in energy, mining and EVs

As investors navigate through another week of market activity, attention remains divided between Toronto and New York, with corporate earnings and a significant U.S. Federal Reserve monetary policy decision dominating discussions. In Toronto, the TSX experienc...
Jonathon Brown | May 2, 2024 |

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Buzz on the Bullboards: Where volatility meets opportunity

It has been a wild ride for markets on Bay Street and Wall Street this week. Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day. It is reporting season for many companies, and Stockhouse users seem...
Jonathon Brown | February 15, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Medicus Pharma advances cancer treatment towards phase II trial

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Our next company is Medicus Pharma Ltd. (TSXV:MDCX) , headquartered in Philadelphia, Pennsylvania. The company is a publicly traded clinical stage, multi-st...
Ryan Dhillon | January 22, 2024 |
1 2 3 4 5 6 7 8 9 10 ...